New immune therapy targets EBV-Linked cancers in early trial
NCT ID NCT05707910
First seen Nov 19, 2025 · Last updated May 24, 2026 · Updated 25 times
Summary
This early-phase study tests a new immune-based treatment for people with advanced tumors linked to the Epstein-Barr virus (EBV) who have not responded to standard therapies. The main goal is to check the treatment's safety in 6 adults aged 18 to 70. Researchers will also look for signs that the treatment shrinks tumors or helps patients live longer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
West China Hospital
Chengdu, Sichuan, 610041, China
Conditions
Explore the condition pages connected to this study.